In a macro view, the Construction & Engineering industry includes companies that design, manufacture and install products for the residential & commercial construction and automotive markets. The industry is characterized by its cyclicality to the U.S. economy. I think the level of new construction or the sales of existing houses will remain favorable, so we are expecting a positive outlook for the sub-industry. With this promising outlook, let's take a look at Gabelli麓s last trade and try to explain to investors the reasons of this appealing investment opportunity.
On Dec. 9, Mario Gabelli added Layne Christensen Company (LAYN). Layne is a water management, construction and drilling company. The company has five segments: Water Resources Division, Inliner Division, Heavy Civil Division, Geoconstruction Division and Mineral Exploration Division.
Key Business
In May 2013, the firm announced the launch of the water transfer business within the Layne Energy Services Division. Layne is currently providing these services for its clients operating in the Permian Basin. This division will provide solutions to address every phase of the water cycle as it relates to its use in the oil and gas industry.
Titan Pharmaceuticals, Inc., incorporated in February 1992, is a biopharmaceutical company developing therapeutics primarily for the treatment of central nervous system (CNS) disorders. The Company is focused primarily on clinical development of products that include Probuphine for the treatment of opioid addiction; Iloperidone: for the treatment of schizophrenia and related psychotic disorders, and Spheramine for the treatment of advanced Parkinson�� disease. Titan Pharmaceuticals is directly developing its product candidates and also utilizing corporate partnerships, including a collaboration with Bayer Schering Pharma AG, Germany (Bayer Schering) for the development of Spheramine to treat Parkinson�� disease, and Vanda Pharmaceuticals, Inc. (Vanda) for the development of iloperidone for the treatment of schizophrenia and related psychotic disorders.
Probuphine
Probuphine is the first product to utilize the Company�� ProNeura long-term drug delivery technology. Probuphine is designed to provide continuous, long-term therapeutic levels of the drug buprenorphine, an approved agent for the treatment of opioid addiction. In December 2007, the Company completed enrollment in a randomized, double-blind, placebo-controlled, multi-center Phase III clinical study of Probuphine in the treatment of opioid addiction. This 150 patient study, which is being conducted in the United States, will evaluate the safety and effectiveness of treatment with Probuphine versus placebo in reducing opioid addiction over 24 weeks of treatment. This study is part of a registration directed program intended to obtain marketing approval of Probuphine for the treatment of opioid addiction in Europe and the United States.
Iloperidone
Iloperidone was evaluated in a Phase III program comprising over 3,500 patients at more than 200 sites in 24 countries, administered and funded by Novartis Pharma AG (Novartis). In three completed efficacy studies conducted by Novartis, ilop! eridone statistically reduced the symptoms of schizophrenia compared to placebo. Iloperidone has also been investigated in three 12-month safety studies, which confirm safety and tolerability. A dose dependent increase in the Q-T Corrected (QTc) interval was observed and investigated further in a clinical study, and no clinically significant adverse events were observed. In September 2007, Vanda submitted a new drug application (NDA) with the United States Food and Drug Administration (FDA) for iloperidone. The NDA for iloperidone was officially accepted for review by the FDA in November 2007.
Spheramine
Spheramine is a cell-based therapeutic that utilizes the Company�� cell-coated microcarrier (CCM) technology, which enables the development of cell-based therapies for minimally invasive, site-specific delivery to the central nervous system of therapeutic factors precisely where they are needed. Spheramine consists of microcarriers coated with human retinal pigment epithelial cells that are intended to enhance brain levels of dopamine, a neurotransmitter deficient in certain brain regions in Parkinson�� disease, leading to movement disorders. Preclinical studies have demonstrated the preliminary efficacy and safety of Spheramine, including blinded studies in a primate model of Parkinson�� disease. In June 2007, enrollment was completed in a current multi-center, randomized, double-blind, placebo-controlled clinical trial of Spheramine in Parkinson�� disease. This Phase IIb clinical study enrolled 71 patients with advanced Parkinson�� disease (Hoehn and Yahr Stages III and IV) to further evaluate the efficacy, safety, and tolerability of Spheramine.
Bayer Schering, the Company�� corporate partner for worldwide development and commercialization of Spheramine, is funding the clinical development program for Spheramine. Under an agreement, Bayer Schering has received exclusive, worldwide development, manufacturing and commercialization rights, and, in ad! dition to! the clinical and manufacturing development funding and milestone payments, Bayer Schering will pay Titan Pharmaceuticals a royalty on future product sales.
Advisors' Opinion: - [By CRWE]
Today, TTNP surged (+2.76%) up +0.018 at $.689 with 152,996 shares in play thus far (ref. google finance Delayed: 2:02PM EDT October 1, 2013).
Titan Pharmaceuticals, Inc. previously reported that the U.S. Food and Drug Administration (FDA) has granted the request for a meeting to discuss Probuphine庐. The meeting is scheduled for November 19, 2013. The FDA has designated this as a Type C meeting and has requested the submission of briefing materials by October 7, 2013.
Best Stocks To Buy For 2014: iShares Cohen & Steers REIT ETF (ICF)
iShares Cohen & Steers Realty Majors Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the Cohen & Steers Realty Majors Index (the Index). The Index consists of selected real estate investment trusts (REITs). The objective of the Index is to represent relatively large and liquid REITs that may benefit from future consolidation and securitization of the United States real estate industry. The Index is modified capitalization-weighted with constituent companies having a maximum index weight of 8%.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. Barclays Global Fund Advisors is the investment advisor of the Fund.
Advisors' Opinion: - [By Matthew McCall]
The SPDR Utilities ETF (NYSE: XLU) is up 1.5 percent today and is breaking to a one-month high. The iShares Cohen & Steers Realty ETF (NYSE: ICF), which owns a basket of REITs, is up 1.1 percent, also looking for a one-month high.
Best Stocks To Buy For 2014: American Lorain Corp (ALN)
American Lorain Corporation (ALN), incorporated on February 4, 1986, is an integrated food manufacturing company. The Company develops, manufactures and sells food products, which includes chestnut products, convenience foods, including ready-to-cook (RTC) foods, ready-to-eat (RTE) foods and meals ready-to-eat (MRE)), and frozen food products. The Company conducts its production activities in China. Its products are sold in 26 provinces and administrative regions in China and 42 foreign countries. The Company derives its revenues from sales in China, Japan and South Korea. During the year ended December 31, 2011, the Company produced 254 products, including 16 new products in its chestnut and convenience foods segment. During 2011, it discontinued three products in the convenience segment. In February 2014, American Lorain Corp acquired a 51% interest in Athena Group.
The Company manufactures its products in six facilities in China, three of which are located in Junan County, Shandong Province, one in Luotian County, Hubei Province, one in Miyun County, Beijing City and one leased facility in Dongguan, Guandong Province. As of December 31, 2011, the Company manufactured its products using 26 production lines. Each production line is used to produce between 10 and 50 products. The Company operates three product lines: deep-freezing lines, canning lines and convenience food lines. The Company sells its products in all first-tier cities in China, including Beijing, Shanghai, Tianjin and Guangzhou. Its export sales destinations include Asia pacific, primarily Japan, South Korea and Malaysia, but also Singapore, Philippines, Indonesia and Australia; Europe, primarily Belgium and the United Kingdom, but also France, Germany, the Netherlands, Spain, Poland, and Denmark the Middle East, primarily Saudi Arabia, Kuwait and Israel; North America, including the United States and Canada.
ALN owns 100% of International Lorain Holding, Inc. (ILH). ILH wholly owns two Chinese operating subsi! diaries, Luotian Green Foodstuff Co., Ltd. (Luotian Lorain) and Junan Hongrun Foodstuff Co., Ltd. (Junan Hongrun), directly. Junan Hongrun, in turn, wholly owns Dongguan Green Foodstuff Co., Ltd. (Dongguan Lorain). In addition, together with Junan Hongrun, ILH wholly owns Beijing Green Foodstuff Co., Ltd. (Beijing Lorain), Shandong Greenpia Foodstuff Co., Ltd. (Shandong Greenpia), and owns approximately 80% of Shandong Green Foodstuff Co., Ltd. (Shandong Lorain) (Shandong Economic Development Investment Co. Ltd. owns approximately 20%).
Chestnut Products
During 2011, the Company produced 57 processed chestnut products. During 2011, this segment contributed 51.7% of its total revenues. The Company's products include its aerated open-bottom chestnuts, which are chestnuts packaged with nitrogen; sweetheart chestnuts, which are sweet preserved chestnuts; chestnuts in syrup, and golden chestnut kernels.
Convenience Foods
The Company's convenience food products include RTC food products, RTE food products and MRE food products. During 2011, the Company's RTCs included beef and lamb products, and its RTEs included bean products and pickle products. The Company's self heating MREs are primarily for military use since no cooking device or other ingredients are needed other than water. The Company also introduced microwavable MREs for civilian uses, such as camping, traveling and other situations. The Company produces various MREs based on Chinese cuisine, which include its pork with garlic sauce over rice and kungpao chicken with rice. The Company produced 138 convenience food products, during 2011, including 14 new products, such as filled buns and fried sweet potato.
Frozen Food Products
The Company produces a variety of frozen foods, including frozen vegetables, frozen fruits, frozen fish, and frozen meats. The Company produced 63 frozen food products in 2011. The Company's frozen foods included, during 2011, were frozen asparagus a! nd frozen! corn.
The Company competes with Hebei Liyuan, Foodwell Corporation, Weifang Langdong Food Co. Ltd., Yuyao Hongji Food Co. Ltd. and Yantai Pengshun Food Co. Ltd.
Advisors' Opinion: - [By James E. Brumley]
Truth be told, were it just today's 11% pop from American Lorain Corporation (NYSEMKT:ALN), it might not even be worth mentioning. It's not just today's 11% rally from ALN, though, that's made this stock so interesting. It's everything that's happened up until this point that may mean American Lorain deserves a spot at the top of your watchlist, if not in your portfolio.
Best Stocks To Buy For 2014: Brown(n)
N Brown Group plc operates as an Internet and catalogue home shopping company in the United Kingdom. The company principally offers womenswear, menswear, footwear, household, and electrical products, as well as provides insurance services. It also operates in the Republic of Ireland, Germany, and the United States. The company was founded in 1859 and is based in Manchester, the United Kingdom.
Advisors' Opinion: Best Stocks To Buy For 2014: Orbotech Ltd.(ORBK)
Orbotech Ltd. engages in designing, developing, manufacturing, marketing, and servicing yield-enhancing and production solutions for specialized applications in the supply chain of the electronics industry. The company?s products include automated optical inspection (AOI), automated optical repair, laser direct imaging, digital legend printing, laser drilling, laser plotters, computer-aided manufacturing, and engineering solutions for printed circuit boards (PCBs) and other electronics component manufacturing; and AOI, test, repair, and process monitoring systems for flat panel display (FPD) manufacturing. It also develops and markets character recognition solutions and services primarily to banks, financial institutions, and other payment processing institutions for use in check and healthcare payment processing. In addition, the company is involved in the research and development of products for the deposition of anti-reflective coating on crystalline silicon photovolta ic wafers for solar energy panels. It primarily serves manufacturer of PCB, FPD, liquid crystal displays, and other electronic components worldwide. The company was formerly known as Optrotech Ltd. and changed its name to Orbotech Ltd. as a result of its merger with Orbot Systems Ltd. in October 1992. Orbotech Ltd. was founded in 1981 and is headquartered in Yavne, Israel.
Advisors' Opinion: - [By Seth Jayson]
Calling all cash flows
When you are trying to buy the market's best stocks, it's worth checking up on your companies' free cash flow once a quarter or so, to see whether it bears any relationship to the net income in the headlines. That's what we do with this series. Today, we're checking in on Orbotech (Nasdaq: ORBK ) , whose recent revenue and earnings are plotted below.
